Phase 1 demonstrates LYT-100 (deupirfenidone)is doseproportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect(FE)

Authors
Category Primary study
JournalEuropean Respiratory Journal
Year 2021
This article has no abstract
Epistemonikos ID: da16c953794a6b7d2cfe52250816f942268d3fbf
First added on: Feb 14, 2025